Extended Data Fig. 9: Aspirin inhibits ENO1- and YAP1-induced liver cancer in vivo.
From: ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism
a, Protein levels of COX2 were measured in PLC cells treated with different doses of aspirin. Actin served as a negative control. b, COX2 enzyme activity was measured in the tumor lysates of Fig. 5b using ELISA (n = 10). c, Protein levels of ENO1 and YAP1 were measured in the tumor lysates of Fig. 5b. Actin served as a negative control. d, Protein levels of mus-ENO1 or mus-YAP1 were measured in Hepa 1–6 cells stably infected with viruses expressing mus-ENO1 or mus-YAP1. e, COX2 enzyme activity was measured in the tumor lysates of Fig. 5e, g using ELISA (n = 5). f, g, Protein levels of ENO1 (Flag), YAP1, PLCB1, and HPGD were measured in the tumor lysates of Fig. 5e, g. Calnexin served as a loading control. h, COX2 enzyme activity was measured in the tumor lysates of Fig. 5i using ELISA (n = 5). i, j, protein (i) and mRNA (j) levels of YAP1, PTGS2 (COX2), PLCB1, and HPGD were detected in the tumor lysates of Fig. 5i. Calnexin served as a loading control. Immunoblots are representative of three independent experiments (a,d). Error bars denote the mean ± s.e.m. (b,e,h,j). Statistical analyses were performed by two-tailed Student’s t-test (b,e,h,j).
